Navigation Links
Echinocandins Show Growth Among All Antifungal Classes
Date:10/30/2008

Merck's Cancidas and Astellas's Mycamine Cut Prices, According To New Data

from Arlington Medical Resources

MALVERN, Penn., Oct. 30 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that echinocandins show growth in the share of courses among all antifungal classes: 10.7 percent of all courses in the January - June 2008 time period compared to 9 percent in the January - June 2007 time period. Echinocandins are a class of antifungal agents consisting of Merck's Cancidas (caspofungin), Astellas's Mycamine (micafungin) and Pfizer's Eraxis (anidulafungin). These agents are commonly used to treat lung tissue infections, disseminated fungal infection and fungemia and are administered intravenously.

"Cancidas currently enjoys the largest share of courses within the echinocandin class (66 percent), followed by Mycamine (22 percent) and Eraxis (13 percent)," stated Joyce Wedemeyer, product director at AMR. "However, Cancidas's share decreased from the previous time period from 74 percent, Mycamine's increased from 13 percent and Eraxis's remained the same at 13 percent."

The newly released U.S. edition of The Hospital Antifungal Market Guide also finds that Cancidas and Mycamine have cut their prices. This cost information is based on hospital acquisition cost.

"Cancidas and Mycamine have both decreased in the average cost/day (in U.S. dollars). Cancidas's average cost/day decreased 12 percent from $174 to $152 and Mycamine's average cost/day decreased 4 percent from $137 to $131," added Ms. Wedemeyer. "However, Eraxis's -the newest of these drugs-average cost/day remained stable at $165."

Why Pharmaceutical Companies Need this Information

The Hospital Antifungal Market Guide enables pharmaceutical companies to monitor inpatient shares, costs and the clinical use of systemic antifungal agents. For every therapeutic drug course there is a link between drug, diagnosis and suspected or confirmed fungal pathogen.

About The Hospital Antifungal Market Guide

The Hospital Antifungal Market Guide is the industry's most comprehensive audit of hospital systemic antifungal drug usage covering acute care hospitals in the United States, Italy, Germany, France, U.K. and Spain. The information in the audit is abstracted directly from hospital source documents from a panel of demographically representative acute care hospitals of all sizes, including transplant centers. The U.S. data is published twice a year and the European data is published once a year.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gentiva Reports Third Quarter Revenue and Profit Growth
2. P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth
7. WILLCARE Chooses Authentidates Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth
8. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
9. Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets
10. The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017
11. Cardica to Present at William Blair Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata ... Spiritual Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally ... individual customized retreats offer the winter-weary soul an excellent opportunity to come out ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
(Date:2/27/2017)... ... ... New Jersey ranks among the top five states in the entire nation ... advanced services is growing. , Project WE vs C is a focused two-year ... non-profit partners in their fight against cancer and in support of their shared mission ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care ... Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade to its ... look for home care close to home, and by having city-specific pages, NuevaCare is ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Wireless ... 23.8% over the next decade to reach approximately $330.5 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Hemophilia market? What are ...
(Date:2/24/2017)... 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... release, you are invited to listen to a conference ... on Tuesday, March 14, 2017 at 4:30 pm Eastern ... audio webcast of the presentation will be available by ... "Investor Relations."  If you are unable to participate during ...
Breaking Medicine Technology: